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The aim of the study was to evaluate the impact of a decision aid (DA) and its timing in women being tested for a BRCA1/2 mutation.
Women with and without a previous history of cancer were included after blood sampling for genetic testing. The DA consisted of a
brochure and video providing information on screening and prophylactic surgery. To evaluate the impact of the DA, women were
randomised to the DA group (n¼184), receiving the DA 2 weeks after blood sampling, or to the control group (n¼184). To
evaluate the impact of timing, mutation carriers who had received the DA before the test result (n¼47) were compared to mutation
carriers who received the DA after the test result (n¼42). Data were collected on well-being, treatment choice, decision and
information related outcomes. The impact of the DA was measured 4 weeks after blood sampling. The impact of timing was
measured 2 weeks after a positive test result. The DA had no impact on well-being. Regarding decision related outcomes, the DA
group more frequently considered prophylactic surgery (P¼0.02) corroborated with higher valuations (P¼0.04). No differences
were found for the other decision related outcomes. Regarding information related outcomes, the DA group felt better informed
(P¼0.00), was more satisfied with the information (P¼0.00), and showed more accurate risk perceptions. Timing of the DA had no
effect on any of the outcomes. No interactions were found between the DA and history of cancer. In conclusion, women being
tested for a BRCA1/2 mutation benefit from the DA on information related outcomes. Because timing had no effect, the DA is
considered useful either before or after the test result.
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The discovery of the BRCA1 and BRCA2 genes has induced
widespread interest in genetic testing for inherited susceptibility of
breast and ovarian cancer (Miki et al, 1994; Wooster et al, 1995).
Women with a BRCA1/2 mutation have a high lifetime risk for
breast cancer (56–85%) and/or ovarian cancer (16–63%) (Easton
et al, 1995; Struewing et al, 1997). They currently face the difficult
choice between screening and prophylactic surgery (Burke et al,
1997).
An important reason to ask for genetic testing is to obtain
certainty about the need for screening and/or prophylactic surgery
(Dudok de Wit et al, 1997; Lynch et al, 1999; Meiser et al, 2000).
These treatment options have different risk–benefit profiles that
women may value differently. The decision about optimal
treatment depends on women’s personal values for the health
states after each of the treatment options (Van Roosmalen et al,
2002). In order to choose between screening and prophylactic
surgery in a way that reflects their personal values, these women
need to be prepared for decision-making by providing information
on the treatment options and their risks and benefits.
Decision aids (DAs) are interventions designed to help people
make specific and deliberative choices among options by
providing information on the options and outcomes relevant to
a person’s health status (O’Connor et al, 2002). Decision aids have
been found to be feasible and acceptable to patients and to increase
the agreement between patients’ values and decisions (Molenaar
et al, 2000). A recent systematic review found that DAs improve
patients’ knowledge and realistic expectations of treatment
options, reduce decisional conflict, and stimulate patients to play
a more active role in decision-making (O’Connor et al, 2002).
Decision aids appeared to have a variable effect on treatment
choice, and little effect on anxiety, satisfaction with the decision-
making process and the decision (O’Connor et al, 2002). The
impact on other outcome measures, such as health outcomes and
persistence with treatment choice, remains uncertain (O’Connor
et al, 2002).
Decision aids in the context of genetic counselling for women
already decided to undergo genetic testing for a BRCA1/2 mutation
is a new development. There is discussion about the timing of
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linforming women about the treatment options. Some believe that
this information should be withheld until after a positive test result
in order to prevent unnecessary burden. Others believe that this
information should be given earlier to achieve full disclosure of the
consequences of a positive test result. Therefore, we investigated
the impact of a DA on a broad range of outcomes and also whether
the time point of presenting information mattered. The DA
consisted of a brochure and video to be viewed at home, providing
information on screening and prophylactic surgery, and the
physical, emotional, and social consequences. The present study
is part of a larger shared decision-making study in which the
impact of another DA, including trade-offs and a formal treatment
advice derived from a decision model (Van Roosmalen et al, 2002),
will be evaluated.
MATERIALS AND METHODS
Participants
We included women with and without a personal history of breast
or ovarian cancer, who provided a blood sample for BRCA1/2
testing at the Family Cancer Clinics of the University Hospitals of
Nijmegen (accrual started March 1999), Groningen (accrual started
June 1999), and Maastricht (accrual started January 2000). These
clinics cover the population of the eastern part of the Netherlands.
The closing date for inclusion was November 2001. Women were
excluded if they had a cognitive disorder that precluded informed
consent, had insufficient knowledge of the Dutch language, were
diagnosed with distant metastases, had undergone both bilateral
mastectomy and oophorectomy, or had been treated with
chemotherapy, radiotherapy, or surgery for breast or ovarian
cancer less than 1 month before blood sampling. The study was
approved by the local research ethics committees.
Intervention
The DA consisted of a brochure and video. Unlike usual
information material, our information concentrated on contrasting
treatment options. The 14-page brochure presented detailed
information on treatment options available in 1998 in the
Netherlands, and on the physical, emotional, and social con-
sequences in qualitative terms, but whenever possible in quanti-
tative terms (see summary of brochure and references in Appendix
A). In the 45min video, we dealt with the consequences of the
treatment options through interviews with eight mutation carriers,
with and without a previous history of cancer, who had chosen for
either screening or prophylactic surgery. In addition, these women
described how they went through the decision-making process.
Shots of the results of prophylactic mastectomy with and without a
reconstruction were shown. The DA was viewed at home. A short
evaluation form was sent with the DA. The video and the
evaluation form were to be returned after 1 week. The DA was
developed in close collaboration with the specialists involved in the
Family Cancer Clinics. It was judged to be balanced in a pretest by
the interviewed mutation carriers, the specialists, and the working
group on familial cancer of the Dutch Society of Psychosocial
Oncology.
Standard procedure at the family cancer clinics
Genetic testing for a BRCA1/2 gene mutation is offered to women
when the family history and the cancer risk estimate suggests a
genetic predisposition. Before blood sampling, usually two
counselling sessions of 1h with a geneticist or genetic counsellor
take place wherein the family history is discussed, a family
pedigree is made, and information is provided on genetic risk,
psychosocial consequences of genetic testing, and briefly on the
possible treatment options. If the woman decides to undergo
genetic testing, a blood sample is obtained. If the mutation is
known in the family, an appointment is made for disclosure of the
test result after 6–12 weeks. Women without a known mutation in
the family receive an invitation for an appointment after extensive
molecular analyses, which may take several months.
When a mutation is found, more detailed information is
provided on the possible treatment options by a geneticist or
genetic counsellor. A social worker or a psychologist is generally
present when a positive test result is disclosed to women
unaffected with cancer. Mutation carriers are offered additional
consultations with a multidisciplinary team involved in the Family
Cancer Clinic, generally consisting of a medical oncologist,
gynaecologist, and surgeon. These appointments usually take
place about 1–2 months after disclosure of a positive test result.
Randomisation and blinding
Randomisation of the DA took place by family (first-degree up to
and including third-degree relatives) to avoid contamination.
Randomisation was computer generated in blocks of 10, and
stratified by personal medical history of breast/ovarian cancer.
Randomisation was performed after obtaining informed consent
and the baseline assessment. Neither subjects nor members of the
study staff were blinded to intervention assignment.
Study procedure
Eligible women were informed about the present study by the
clinical geneticist or genetic counsellor after blood sampling for
genetic testing. Women were subsequently contacted by a research
assistant to confirm eligibility and to inform them about the study.
Women who gave verbal consent were enrolled and received an
informative letter describing the study, a consent form, and the
baseline questionnaire T1. Women, awaiting their test result, were
randomly assigned to the DA group, who received the DA 2 weeks
after blood sampling, or to the control group, who received no
additional information (see Figure 1). At 4 weeks after blood
sampling (T2), the impact of the DA was evaluated by comparing
the DA group with the control group (see Figure 1). Women from
the DA group who tested positive (i.e. a BRCA1 or BRCA2
mutation was found) had received the DA before the test result
(DA_b), and women from the control group subsequently received
the DA after the positive test result (DA_a). At 2 weeks after a
positive test result (T3), the impact of timing of the DA was
assessed by comparing the DA_b group with the DA_a group (see
Figure 1). Data were collected using questionnaires.
MEASURES
Baseline characteristics
Data were obtained on sociodemographic (age, marital status,
education level, employment status, presence of children, wanting
(more) children, and being religiously affiliated) and medical
background (personal and family history of breast/ovarian cancer,
time since last cancer diagnosis, whether a mutation was known in
the family, whether first-degree relatives had breast or ovarian
cancer, and whether they died from breast or ovarian cancer).
Well-being
We collected data on anxiety (state scale of the Spielberger State–
Trait Anxiety Inventory) (Spielberger et al, 1983), depression
(Center for Epidemiologic Studies Depression Scale) (Radloff,
1977), and cancer related distress (Impact of Event Scale)
(Horowitz et al, 1979). Furthermore, we asked women to rate
their general health state during the last week on a 11-point scale
ranging from 0 (very bad health state) to 10 (excellent health state).
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Treatment choice was asked for both breasts and ovaries. The
treatment choice related to breast cancer risk was between
‘prophylactic mastectomy’, ‘breast cancer screening’, and ‘unde-
cided’. The treatment choice related to ovarian cancer risk was
between ‘prophylactic oophorectomy’, ‘ovarian cancer screening’,
and ‘undecided’. Valuations for the treatment options were asked
on a 10-point scale ranging from 1 (very bad) to 10 (excellent).
Decision related outcomes
The decision related outcomes were asked separately for the
breasts and ovaries. An overall score was created by adding the
scores for the decision related to breast and ovarian cancer risk
and dividing this by the number of items included.
Strength of treatment preference was asked on a 4-point Likert
scale ranging from 1 (weak preference) to 4 (very strong
preference). Those who filled out ‘undecided’ as treatment choice
were assigned a value of 0 (no preference).
Decision uncertainty was measured with three items related to
the uncertainty subscale of the Decisional Conflict Scale by
O’Connor (1995). The items were: ‘I doubt what to choose,’ ‘This
decision is hard for me to make,’ and ‘I am not sure what to
choose,’ measured on a 5-point scale ranging from 1 (very much
disagree) to 5 (very much agree).
Preference for decision-making was measured with the two
decision-making items from the Problem-Solving Decision-Mak-
ing Scale (PSDM) by Deber et al (1996). The items were: ‘Given the
risks and benefits of the possible treatment options, who should
decide how acceptable those risks and benefits are for you,’ and
‘Given the risks and benefits of the possible treatment options,
who should decide which treatment option should be selected,’
measured on a 5-point scale ranging from 1 (doctor alone) to 5 (I
alone).
Information related outcomes
Subjective knowledge was measured by asking women to rate their
knowledge for prophylactic mastectomy, breast cancer screening,
breast self-examination, prophylactic oophorectomy, and ovarian
cancer screening, on a 10-point scale ranging from 1 (very bad) to
10 (excellent). An overall score for subjective knowledge was
created by adding the scores on the five items and dividing this by
five.
The amount of received information was measured on a 7-point
scale ranging from 1 (I received way too little information), 4 (I
received exactly enough information), to 7 (I received way too
much information), for the decision related to breast and ovarian
cancer risk. An overall score was created by adding the scores and
dividing this by two.
Satisfaction with quality of information was measured with a 13-
item questionnaire on a 6-point scale ranging from 1 (not
satisfied), 4 (rather satisfied), to 6 (very much satisfied). Women
were offered a series of items regarding cancer risks, efficacy of
treatment options, and physical, emotional, and social conse-
quences. An overall score was created by adding the scores on the
13 items and dividing this by 13.
Risk perception was asked for the following eight items (the
range that we considered accurate for subsequent analyses is given
in parentheses): breast (8–14%) and ovarian cancer risk (1–3%)
in the general female population, breast (60–85%) and ovarian
cancer risk (15–60%) in BRCA1/2 mutation carriers, the
possibility of cure when breast (65–80%) and ovarian cancer
(35–50%) is detected during screening in BRCA1/2 mutation
carriers, and residual risk after prophylactic surgery of breasts (3–
12%) and ovaries (3–12%) in mutation carriers. Women were
asked to give a risk estimate in a range from 0 to 100%. For each
item, a new variable was created classifying the risk estimate as
underestimate, accurate, or overestimate. In the analyses, risk
accuracy was dichotomised in accurate and inaccurate.
We did not assess the amount of received information,
satisfaction with quality of information, and risk perception at
baseline to avoid information-seeking behaviour in the control
group, thus making the control group less representative.
Sample size
To detect a difference of at least 10% in the decision uncertainty
score between the DA and control groups, with a 5% two-sided
significance level and a power of 80%, we needed a sample size of
180 women in each group.
Statistical analyses
We analysed data from women who completed the questionnaire
at baseline and at the time point of interest on an intention to treat
basis. In multi-item scales with missing data, scale values were
calculated if at least half of the items were filled out by imputing
the mean of the remaining items. We compared the intervention
groups at baseline using w
2 tests for categorical variables, and t-
tests for continuous variables. To evaluate the impact of the DA,
we compared the DA group with the control group at T2 (see
Figure 1). To evaluate the impact of timing of the DA, we
T3
Followed up n=47
DA_b group
Followed up n=47
X
Test result
Positive n=47
(Negative n=50)
(Inconclusive n=87)
Test result
Positive n=44
(Negative n=46)
(Inconclusive n=94)
T2
Followed up n=184
Withdrew n=4
Followed up n=184
Withdrew n=6
DA group
Followed up n=188
Withdrew n=6
DA
T3
Followed up n=42
DA_a group
Followed up n=42
Withdrew n=2
DA
T2
Control group
Followed up n=190
X
Randomisation
T1
Followed up n=384
Withdrew n=6
Informed consent n=390
Nonconsent n=63
Eligible n=453
Ineligible n=57
Blood sample n=510
Evaluation of 
impact of DA
Evaluation of 
timing of DA
Figure 1 Participant flow.
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Figure 1). For continuous variables, comparisons between inter-
vention groups were made using analyses of covariance (ANCO-
VA) (Maxwell and Delaney, 1990). The baseline assessment of the
outcome measure, when present, was included as a covariate.
Baseline characteristics tabulated in Table 1, which differed
between the intervention groups (Po0.10), were also included as
covariate. Effect sizes (d) were calculated as the adjusted mean of
the DA group minus the adjusted mean of the control group, and
as the adjusted mean of the DA_b minus the adjusted mean of the
DA_a group, divided by the standard deviation of the difference
score. For two categorical variables, namely ‘treatment choice’ and
‘accuracy of risk perception’, comparisons between groups were
made using w
2 tests. We used a P level of 0.05 to indicate statistical
significance. The number of subjects providing data for the various
analyses varied due to missing data.
Because randomisation took place by family, and because family
members were not independent on the outcome measures,
statistical significance will be inflated when all women are treated
as independent units. At baseline, we included 33 families with
multiple participating members (range 2–5), with a total of 80
women. The subsample of mutation carriers consisted of 10
families with multiple members (range 2–3), with a total of 23
women. To counter inflation, we further examined significant
effects by incorporating only the first included family member in
the analyses.
In a previous study of ours, we found that after blood
sampling for genetic testing, women affected with breast or
ovarian cancer reported a worse well-being and a lower
preference for participation in decision-making than women
without a previous history of cancer (Van Roosmalen et al,
2003). To explore a possible differential impact of the DA in
women with and without a history of cancer, we examined
interactions between the DA (and its timing) and history of cancer
using the ANCOVA.
RESULTS
Participants
The participant flow is presented in Figure 1. During the study
period, 510 women were ascertained of whom 453 (89%) were
eligible. Of these 453 women, 390 (86%) gave informed consent. At
T1, six (2%) women withdrew. Of the remaining 384 women, 194
were randomised to the DA group and 190 to the control group. Of
the 194 women from the DA group, six (3%) withdrew: four
indicated an emotional burden related to being informed, one
indicated that she did not want to fill out any more questionnaires
for emotional reasons, and one indicated that the study was too
time consuming. Of the remaining 188 women from the DA group,
four (2%) did not view the DA because of an emotional burden.
These four women remained in the study and were analysed on an
intention to treat basis. At T2, four (2%) women withdrew in the
DA group and six (3%) in the control group. In both groups, none
of the women declined to receive their test result. In the DA group,
47 (26%) women received a positive test result (38 BRCA1, nine
BRCA2). In the control group, 44 (24%) women received a positive
test result (28 BRCA1, 14 BRCA2). Mutation carriers from the DA
group had received the DA before the test result (DA_b). Mutation
carriers from the control group subsequently received the DA after
the test result (DA_a). Of the 44 women from the DA_a group, two
(5%) withdrew because of high emotional distress caused by the
test result; it is unclear whether their withdrawal was also related to
the DA. Of the remaining 42 women from the DA_a group, all
viewed the DA. At T3, none of the women withdrew.
Baseline characteristics
Table 1 presents the sociodemographic and medical background,
and the baseline assessment of well-being. Between the DA and
control groups, significant differences were found for being
Table 1 Baseline characteristics by intervention group
DA (n¼184) Control (n¼184) DA_b (n¼47) DA_a (n¼42)
Sociodemographic background
Age: mean (s.d.) 43.7 (11.3) 43.5 (10.4) 38.7 (10.0) 40.3 (9.9)
Currently married/partner (%) 84 85 85 86
College or higher (%) 37 32 30 43
Employed (%) 65 65 70 69
Have children (%) 80 83 75 69
Want (more) children (%) 17 15 22 28
Being religiously affiliated (%) 57* 71* 52
w 74
w
Personal medical history
No cancer (%) 46 49 70 76
Breast cancer only (%) 49 46 30 24
Ovarian cancer only (%) 4 4 0 0
Breast and ovarian cancer (%) 1 1 0 0
Family medical history
Breast cancer only (%) 47 54 27 20
Ovarian cancer only (%) 3 3 0 3
Breast and ovarian cancer (%) 50 43 73 77
Known familial mutation (%) 47 44 77 76
First-degree relatives with bc or oc (%) 66 69 71 77
First-degree relatives died of bc or oc (%) 28 27 34 31
Well-being
Anxiety: mean (s.d.) 40.9 (11.4)* 38.6 (10.7)* 40.1 (10.6) 37.4 (11.5)
Depression: mean (s.d.) 9.3 (8.6) 8.4 (8.1) 7.5 (7.1) 8.6 (8.6)
Cancer related distress: mean (s.d.) 20.1 (14.8) 18.1 (13.5) 18.5 (13.8) 17.1 (12.9)
General health: mean (s.d.) 7.3 (1.7)* 7.6 (1.4)* 7.9 (1.4) 8.0 (1.5)
bc: breast cancer; oc: ovarian cancer. *Po0.10 comparing the DA and control groups.
wPo0.10 comparing the DA_b and DA_a groups.
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mutation carriers in the DA_b and DA_a groups, a significant
difference was found for being religiously affiliated.
Evaluation of the decision aid
The DA was viewed once by 49%, and twice or more by 51%. Most
respondents (82%) found that it contained exactly enough
information, and 13% stated that it contained slightly too little
information. In all, 56% reported no negative, 31% a scarcely
negative, 12% a rather negative, and 1% a negative emotional
reaction towards the information provided. The evaluation forms
contained predominantly positive remarks.
Impact of the decision aid
Well-being No significant differences were found between the DA
and control groups for anxiety, depression, cancer related distress,
and general health (Table 2).
Treatment choice At baseline (T1), no significant differences
were found between the DA and control groups (Table 4). At T2,
significant differences were found; women in the DA group more
often chose for prophylactic surgery. For the valuation of the
treatment options (Table 2), significant differences were found
between the DA and control groups; women in the DA group gave
a higher value for prophylactic surgery and a lower value for
screening, corroborating our finding of more choices for
prophylactic surgery.
Decision related outcomes For strength of treatment preference,
decision uncertainty, and preference for decision-making (Table 2),
no significant differences were found.
Information related outcomes For subjective knowledge, amount
of received information, and satisfaction with quality of informa-
tion (Table 2), significant differences were found between the DA
and control groups; women in the DA group felt better informed
and were more satisfied with the amount and quality of the
information.
The mean risk estimates, the percentage under-, accurate,
and overestimates, are presented in Table 5. Significant
differences were found in risk accuracy for three of the eight
items; the DA group made significantly more accurate risk
estimates for BRCA1/2 related ovarian cancer risk, and cure of
BRCA1/2 related breast cancer diagnosed during screening
and cure of BRCA1/2 related ovarian cancer diagnosed during
screening.
Impact of timing of the decision aid
For well-being, decision and information related outcomes
(Table 3), and treatment choice (Table 4), no significant
differences were found between the mutation carriers in the
DA_b and DA_a groups, with the exception that the DA_a
group made significant more accurate risk estimates for cure of
BRCA1/2 related ovarian cancer diagnosed during screening
(Table 5).
Table 2 Impact of DA: unadjusted mean scores (s.d.), results and effect sizes (d) from the ANCOVA comparing the DA and C groups
Group n T1 T2 F Pd
Well-being
Anxiety (STAI-state) DA 176 41.0 (11.4) 40.4 (11.3)
C 174 38.3 (10.6) 37.3 (10.6) 1.90 0.17 0.10
Depression (CESD) DA 176 9.3 (8.6) 8.7 (8.9)
C 175 8.1 (7.6) 7.5 (7.3) 0.02 0.89 0.01
Cancer related distress (IES) DA 169 19.9 (14.7) 18.6 (15.0)
C 174 17.6 (13.1) 16.3 (14.2) 0.14 0.71 0.03
General health DA 173 7.3 (1.7) 7.4 (1.5)
C 172 7.7 (1.5) 7.6 (1.6) 0.25 0.62 0.04
Decision related outcomes
Valuation of PM DA 164 5.1 (2.6) 5.6 (2.5)
C 160 4.8 (2.5) 5.0 (2.6) 4.41 0.04 0.17
Valuation of BS DA 165 7.2 (2.5) 6.5 (2.5)
C 162 7.5 (2.2) 7.4 (2.1) 14.86 0.00  0.30
Valuation of PO DA 161 6.9 (2.3) 7.4 (2.2)
C 160 6.7 (2.6) 6.9 (2.5) 4.29 0.04 0.16
Valuation of OS DA 160 5.9 (2.8) 4.9 (2.5)
C 159 6.3 (2.9) 6.0 (2.7) 15.64 0.00  0.31
Strength of treatment preference DA 150 2.7 (1.1) 2.6 (1.0)
C 150 2.7 (1.1) 2.7 (1.0) 1.38 0.24  0.10
Decision uncertainty DA 157 2.7 (1.1) 2.6 ( 0.9)
C 162 2.8 (1.1) 2.7 (1.0) 1.20 0.27  0.09
Preference for decision-making DA 155 3.7 (0.6) 3.8 (0.6)
C 159 3.5 (0.6) 3.7 (0.6) 1.46 0.23  0.10
Information related outcomes variables
Subjective knowledge DA 176 6.1 (1.5) 6.8 (1.3)
C 174 6.1 (1.5) 6.3 (1.4) 22.31 0.00 0.36
Amount of received information DA 171 * 3.2 (0.9)
C 166 * 2.5 (1.0) 50.37 0.00 0.54
Satisfaction quality information DA 176 * 3.8 (0.9)
C 171 * 3.2 (1.0) 28.48 0.00 0.40
C: control; PM: prophylactic mastectomy; BS: breast cancer screening; PO: prophylactic oophorectomy; OS: ovarian cancer screening; *not measured at baseline (T1).
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lTable 3 Impact of timing of DA: unadjusted mean scores (s.d.), results and effect sizes (d) from the ANCOVA comparing the DA_b and the DA_a
groups
Group n T1 T3 F Pd
Well-being
Anxiety (STAI-state) DA_b 45 40.3 (10.8) 40.9 (12.9)
DA_a 40 37.8 (11.5) 40.2 (12.4) 0.25 0.62  0.08
Depression (CESD) DA_b 45 7.7 (7.2) 11.2 (11.0)
DA_a 39 8.6 (8.8) 9.4 (9.4) 2.42 0.12 0.24
Cancer related distress (IES) DA_b 44 18.4 (13.5) 22.6 (15.7)
DA_a 40 17.3 (13.1) 20.3 (13.9) 0.36 0.55 0.09
General health DA_b 43 7.8 (1.5) 7.4 (1.9)
DA_a 37 8.0 (1.5) 7.7 (1.7) 0.23 0.63  0.08
Decision related outcomes
Valuation of PM DA_b 44 5.0 (2.4) 5.6 (2.5)
DA_a 39 4.0 (2.4) 4.7 (2.7) 0.02 0.89 0.02
Valuation of BS DA_b 44 7.3 (2.4) 6.3 (2.3)
DA_a 39 8.2 (1.6) 7.4 (2.1) 1.16 0.29  0.17
Valuation of PO DA_b 41 6.7 (2.7) 7.3 (2.6)
DA_a 38 5.8 (2.8) 6.5 (2.5) 0.09 0.77 0.05
Valuation of OS DA_b 41 5.6 (2.9) 4.7 (2.8)
DA_a 38 7.2 (2.5) 6.2 (2.8) 0.80 0.38  0.14
Strength of treatment preference DA_b 40 2.8 (1.2) 3.1 (0.8)
DA_a 36 2.6 (1.1) 2.8 (1.0) 0.64 0.43 0.13
Decision uncertainty DA_b 43 2.5 (1.1) 2.1 (0.9)
DA_a 38 2.7 (1.1) 2.4 (1.0) 0.29 0.59  0.08
Preference for decision-making DA_b 42 3.8 (0.6) 3.8 (0.7)
DA_a 37 3.5 (0.6) 3.6 (0.7) 0.17 0.69  0.06
Information related outcomes variables
Subjective knowledge DA_b 45 6.2 (1.8) 7.1 (1.3)
DA_a 40 6.1 (1.5) 6.8 (1.4) 0.83 0.37 0.14
Amount of received information DA_b 43 * 3.3 (0.9)
DA_a 40 * 3.3 (0.9) 0.25 0.62 0.08
Satisfaction quality information DA_b 45 * 3.9 (1.0)
DA_a 38 * 3.7 (0.9) 1.01 0.32 0.15
PM: prophylactic mastectomy; BS: breast cancer screening; PO: prophylactic oophorectomy; OS: ovarian cancer screening; *not measured at baseline (T1).
Table 4 Treatment choice related to breast and ovarian cancer risk at T1 and T2 (for the DA and control groups) or T3 (for the DA_b and DA_a
groups)
DA Control DA_b DA_a
Treatment choice related to bc risk at T1 T1
Prophylactic mastectomy 61 (35) 53 (31) 17 (37) 8 (20)
Breast cancer screening 92 (53) 103 (60) 24 (52) 30 (73)
Undecided 20 (12) 15 (9) 5 (11) 3 (7)
w
2¼1.89; P¼0.39 w
2¼4.13; P¼0.13
Treatment choice related to bc risk at T2 T3
Prophylactic mastectomy 69 (41) 55 (32) 18 (40) 8 (21)
Breast cancer screening 80 (47) 104 (61) 26 (58) 29 (74)
Undecided 21 (12) 11 (7) 1 (2) 2 (5)
w
2¼7.84; P¼0.02 w
2¼3.94; P¼0.14
Treatment choice related to oc risk at T1 T1
Prophylactic oophorectomy 112 (66) 105 (62) 27 (61) 21 (51)
Ovarian cancer screening 36 (21) 44 (26) 10 (23) 15 (37)
Undecided 21 (13) 20 (12) 7 (16) 5 (12)
w
2¼1.05; P¼0.59 w
2¼1.98; P¼0.37
Treatment choice related to oc risk at T2 T3
Prophylactic oophorectomy 122 (73) 107 (63) 34 (81) 22 (56)
Ovarian cancer screening 24 (14) 48 (28) 6 (14) 14 (36)
Undecided 21 (13) 14 (8) 2 (5) 3 (8)
w
2¼10.37; P¼0.01 w
2¼5.87; P¼0.05
bc: breast cancer; oc: ovarian cancer. Values are numbers (percentage) of women.
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family member
Significant differences found above were further tested by
including only the first family member. Differences between the
DA and control groups were no longer significant for the valuation
of prophylactic mastectomy (P¼0.13), the valuation of prophy-
lactic oophorectomy (P¼0.15), and risk accuracy of BRCA1/2
related ovarian cancer risk (P¼0.18).
Interaction between the decision aid (and its timing) and
history of cancer
No interactions were found between the DA and history of cancer.
No interactions were found between timing of the DA and history
of cancer, except for valuation of prophylactic mastectomy
(Po0.01) and breast cancer screening (Po0.01). Women affected
with cancer valued prophylactic mastectomy higher and breast
cancer screening lower in the DA_a group compared to the DA_b
group, whereas for women without a previous history this was in
the opposite direction.
DISCUSSION
The present study is the first to evaluate the impact of a DA and its
timing in women being tested for a BRCA1/2 mutation. Both
women with and without a previous history of cancer were
included. The brochure and video were designed to help women
make informed decisions, and concentrated on contrasting the
various risks and benefits of screening and prophylactic surgery
and the physical, emotional, and social consequences. The DA had
no impact on well-being. The DA led to more considerations
towards prophylactic surgery and corroborating higher valuations
for prophylactic surgery. The DA had no impact on strength of
treatment preference, decision uncertainty, and preference for
decision-making. The DA improved information related outcomes.
In general, timing of the DA had no impact on any of the outcome
measures. No interactions were found between the DA and history
of cancer.
Previous studies on genetic testing for a BRCA1/2 mutation did
not find substantial psychological morbidity among women
initiating genetic testing or receiving a positive test result (Lerman
et al, 1996, 1998; Croyle et al, 1997; Lodder et al, 1999, 2001; Coyne
et al, 2000; Schwartz et al, 2002), which is in agreement with the
well-being levels in our study. The DA had no negative impact on a
broad range of well-being outcomes, and did not deter women
from receiving their test result, while it improved understanding of
the treatment options and consequences. Similar results on the use
of a video in BRCA1/2 counselling have been reported (Cull et al,
1998). Their video, however, was more general and introductory
and less focused on the treatment decision. Another difference is
that it was provided either before or after the first genetic
counselling session, whereas our information was provided after a
blood sample was taken or after a positive test result.
Women in the DA group were more inclined towards
prophylactic surgery. This was surprising as the DA was judged
to be balanced in a pretest. It also described the negative
consequences of prophylactic surgery in words and pictures. The
trend of the decision towards prophylactic surgery, while
interesting, is not a valid criteria for judging the DA. Therefore,
a more relevant question is whether the DA led to a reduction of
decision uncertainty, and whether it stimulated a preference for a
more active role in decision-making; our results did not show such
benefits despite the fact that women felt better informed about the
treatment options. As our DA was simple and was to be viewed at
home, that is without face-to face support, a more intensive DA
might prove more effective (O’Connor et al, 2002).
The largest and most consistent benefits of DAs are better
knowledge and more realistic expectations of treatment options
(O’Connor et al, 2002). We also found that women felt better
informed, were more satisfied with the amount and quality of the
information, and had more accurate risk perceptions, after viewing
the DA. A clear marker of the information need is that most
women viewed the DA, and about half of the women viewed the
DA twice or more. Only a few women did not want to see the DA
while awaiting their test result. Despite improvements in risk
perception, on average 60% of women in the DA group still had
risk perceptions that were inconsistent with a broadly defined
range of accuracy. Further research is needed to enhance risk
Table 5 Mean risk perception (s.d.), percentage under- ( ), accurate (¼), and overestimates (+) by intervention group
T2 T3
Group Mean (s.d.)  (%) ¼(%) +(%) Group Mean (s.d.)  (%) ¼(%) +(%)
General
bc risk DA 25.3 (17.4) 2 41 57 DA_b 20.4 (18.6) 9 56 35
C 27.0 (19.8) 3 38 59 DA_a 21.0 (18.8) 5 59 36
oc risk DA 20.3 (17.9) 1 11 88 DA_b 16.4 (21.0) 2 24 74
C 21.1 (18.4) 2 7 91 DA_a 11.9 (12.8) 0 21 79
BRCA1/2
bc risk DA 65.2 (17.4) 40 57 3 DA_b 70.6 (14.7) 28 68 4
C 62.8 (19.2) 43 53 4 DA_a 69.5 (15.3) 27 70 3
oc risk* DA 55.6 (18.9) 3 65 32 DA_b 52.6 (17.7) 2 73 24
C 55.5 (21.7) 7 54 39 DA_a 48.7 (20.5) 5 72 23
Cure bc* DA 60.4 (21.3) 49 43 8 DA_b 61.9 (24.2) 39 50 11
C 56.2 (12.4) 59 32 9 DA_a 68.0 (17.1) 34 58 8
Cure oc*
w DA 44.7 (22.0) 33 38 37 DA_b 37.9 (26.7) 48 24 28
C 45.3 (26.9) 39 24 29 DA_a 40.4 (22.4) 32 47 21
bc risk after PM DA 10.3 (15.0) 37 43 20 DA_b 8.1 (9.3) 41 41 18
C 15.8 (20.8) 30 38 32 DA_a 8.7 (9.4) 38 42 20
oc risk after PO DA 8.7 (14.4) 50 32 18 DA_b 6.3 (9.3) 48 39 13
C 13.0 (20.5) 41 32 27 DA_a 6.7 (6.8) 45 38 17
C: control; bc: breast cancer; oc: ovarian cancer; PM: prophylactic mastectomy; PO: prophylactic oophorectomy. *Po0.05 for risk accuracy comparing the DA and control
groups.
wPo0.05 for risk accuracy comparing the DA_b and DA_a groups.
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whether it was presented before or after the test result.
The strength of our study is that we included a consecutive
sample of women covering the eastern part of the Netherlands.
Some limitations should be considered. First, we did not evaluate
the impact of timing of the DA in women receiving an inconclusive
test result (n¼181). This was beyond the scope of our study,
which focused on mutation carriers subsequently. Second, the
subsample of mutation carriers is relatively small reducing the
power to detect meaningful differences between the women who
received the DA either before or after the test result. Third, all
treatment choices, even those obtained 2 weeks after a positive test
result, are merely intentional as prophylactic surgery is usually
postponed for several months until all specialists have been
consulted or even longer in young women. However, additional
clinical follow-up showed that intended treatment choices,
obtained shortly after a positive test result (T3), are strongly
predictive of the executed treatment at 9 months after a positive
test result: for example, 53% of the women opting for prophylactic
mastectomy had undergone this treatment, compared to none of
the women opting for breast cancer screening. Fourth, long-term
follow-up on the effects of the DA was not obtained because all
mutation carriers eventually had received the DA. In the second
part of our study, evaluating another DA, including trade-offs and
a formal treatment advice derived from a decision model (Van
Roosmalen et al, 2002), the follow-up of these mutation carriers
will be continued. The brochure was based on the best knowledge
available at that time and needs regular updates. Our results
showed that it does not matter whether the DA is given to women
before or after disclosure of the BRCA1/2 test result. However, in
the waiting period before the test result, women do benefit from
the DA on information related outcomes such as subjective
knowledge, satisfaction with the amount and quality of informa-
tion, and risk perception. Only few women may prefer to postpone
the DA until being tested positive. Positive effects occurred
irrespective of history of cancer; thus the DA is considered useful
both for women with and without a previous history of cancer.
Therefore, our advice is to offer the DA, in addition to genetic
counselling, to all women on a voluntary basis after taking the
blood sample, while making clear that the information is also
available after the test result.
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Appendix A: Summary of information presented in the
brochure
Introduction
Aim of information material:
supplementary information to genetic counselling.
General information:
procedures at the Family Cancer Clinic, patterns of inheritance,
outline of choices.
Breast cancer
Sporadic breast cancer:
11% lifetime risk (Netherlands Cancer Registry, 1995), mostly
occurs after the age of 50, general risk factors.
Hereditary breast cancer:
35–50% risk before age 50, 60–85% lifetime risk (Easton et al,
1995; Struewing et al, 1997), characteristics of hereditary breast
cancer.
Breast cancer screening
Efficacy: 80% of breast cancers detected in early stage
during screening, 70–75% of these breast
cancers are curable (Smart et al, 1997).
Prognosis about the same as sporadic breast
cancer (Verhoog et al, 1998), not everybody
will develop breast cancer during screening.
Procedure: generally from age 25, monthly breast self-
examination, 6-monthly physical examination
by a physician, yearly mammography.
Additional information:
surgery for breast cancer, future developments, MRI, biopsies.
Psychosocial consequences:
more awareness of physical symptoms of the body sometimes may
lead to more physical complaints, worse psychological well-being
in some women due to fear of cancer, which may affect marital
relationships. Better coping with the situation over time.
Prophylactic mastectomy
Efficacy: small remaining risk of breast cancer (Hart-
mann et al, 1999).
Procedure: about 1 week admission in hospital, healing of
wound takes some time, mostly without
complications, no lymphoedema.
Additional information:
breast reconstruction and alternatives, consequences and compli-
cations.
Psychosocial information:
mostly a deliberated choice and therefore better accepted, feelings
of relieve, negative impact on body image and sexuality in some
women. Better cooping with situation over time.
Ovarian cancer
Sporadic ovarian cancer:
1.8% lifetime risk (Netherlands Cancer Registry, 1995), mostly
occurring at age 45–60, general risk factors.
Hereditary ovarian cancer:
BRCA1 40–60% lifetime risk, BRCA2 15–20% lifetime risk, low
risk before age 40, sharp increase from age 40 (Easton et al, 1995;
Struewing et al, 1997).
Ovarian cancer screening
Efficacy: efficacy unproven, 25% of ovarian cancer
detected in early stage in unscreened popula-
tion (Ries et al, 1973–1998), 40–45% of
hereditary ovarian cancer is curable, indication
of better prognosis for hereditary as compared
to sporadic ovarian cancer (Rubin et al, 1996),
not everybody will develop ovarian cancer
during screening.
Procedure: generally from age 35, yearly transvaginal
ultrasound, gynaecologic examination, CA125
testing.
Additional information:
future developments, biopsies, surgery for ovarian cancer.
Psychosocial consequences:
more awareness of physical symptoms of the body sometimes may
lead to more physical complaints, worse psychological well-being
in some women due to fear of cancer, which may affect marital
relationships. Better cooping with the situation over time.
Prophylactic oophorectomy
Efficacy: small remaining risk of ovarian cancer (Piver
et al, 1993).
Procedure: mostly around age 40, about 2 days admission
in hospital, usually laparoscopic surgery with
minimal morbidity, after surgery ongoing
CA125 control.
Additional information:
menopause and consequences (increased risk for cardiovascular
diseases and osteoporosis), hormone replacement therapy and
consequences.
Psychosocial information:
most complaints due to effect of menopause.
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